AIP
AST

Ameritas Investment Partners’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Ameritas Investment Partners’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-815
Closed -$1K – 3164
2018
Q1 		$1K Hold
815
– – ﹤0.01% 2949
2017
Q4 		$2K Hold
815
– – ﹤0.01% 2943
2017
Q3 		$2K Hold
815
– – ﹤0.01% 2978
2017
Q2 		$3K Hold
815
– – ﹤0.01% 2974
2017
Q1 		$3K Buy
+815
New +$3.17K ﹤0.01% 2916

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Ameritas Investment Partners's AST Position: Q2 2018 in Review

Ameritas Investment Partners sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 815 shares — an estimated $1K sold.

Ameritas Investment Partners first reported a position in AST in Q1 2017 and held it in 5 quarters. The position peaked at $3K in Q2 2017. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

  • Ameritas Investment Partners reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
  • Ameritas Investment Partners sold 815 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $1K.
  • Ameritas Investment Partners first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2017 and held it in 5 quarters.
  • Ameritas Investment Partners's Asterias Biotherapeutics Inc. Series A position peaked at $3K in Q2 2017.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on Ameritas Investment Partners's 13F filing for Q2 2018, filed 13 Aug 2018.